Adverse effects of medication

Author/s
Eric Taylor
Citation
Issue 2 Spring 2012
CEPiP.2012.1.51-57
Abstract

The commonest adverse effects of methylphenidate and dexamfetamine are appetite suppression, weight loss and sleep disturbance, although sometimes sleep is improved. There can be a modest effect of stimulant medication on decreasing growth velocity, but even this can be avoided by regular monitoring and adjustment of dosage or preparation when needed. Tics are not a contraindication to stimulant medication but exacerbation of tics may warrant dose reduction or change of medication. Both stimulant medication and atomoxetine can increase blood pressure, but any increases are usually small. The risk of sudden death does not appear to be increased by stimulant medication. Routine ECGs are not recommended. Specialist opinion should, however, be sought before medication is commenced for patients with a relevant personal or family cardiac history. Baseline measurement and regular follow-up monitoring of blood pressure, pulse, height (in children) and weight are recommended for patients taking stimulant medication or atomoxetine. The potential for substance misuse is probably not increased by prescribing medication for ADHD. Psychotic symptoms are only rarely associated with ADHD treatment. Most of the adverse effects of licensed medication for ADHD are mild and/or easily reversible.

Cite as: Cutting Edge Psychiatry in Practice 2012, 2(1):51-57; https://doi.org/10.65031/zcql1975

References

  1. Cortese S, Faraone S V, Konofal E, and Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta- analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry 2009; 48:894-908 https://doi.org/10.1097/chi.0b013e3181ac09c9
  2. Sangal RB, Owens J, Allen A J, Sutton V, Schuh K, and Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29:1573-1585 https://doi.org/10.1093/sleep/29.12.1573
  3. Wilens TE, Biederman J, and Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad.Child Adolesc.Psychiatry 1994; 33:424-426 https://doi.org/10.1097/00004583-199403000-00018
  4. Bendz LM. and Scates AC. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. The Annals of Pharmacotherapy 2010; 44:185-191 https://doi.org/10.1345/aph.1m365
  5. Rothenberger A, Roessner V, Banaschewski T, and Leckman JF. Co-existence of tic disorders and attention-deficit/ hyperactivity disorder-recent advances in understanding and treatment. Eur.Child Adolesc Psychiatry 2007; 16 Suppl 1:1-4 https://doi.org/10.1007/s00787-007-1001-9
  6. Poncin Y, Sukhodolsky DG, McGuire J, and Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. Eur.Child Adolesc Psychiatry 2007; 16 Suppl 1:78-88 https://doi.org/10.1007/s00787-007-1010-8
  7. Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, and Walkup J. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006; 3:192-206 https://doi.org/10.1016/j.nurx.2006.01.009
  8. Roessner V, Robatzek M, Knapp G, Banaschewski T, and Rothenberger A. First-onset tics in patients with attention-deficit- hyperactivity disorder: impact of stimulants. Dev.Med Child Neurol. 2006; 48:616-621 https://doi.org/10.1017/s0012162206001290
  9. Bloch MH, Panza KE, Landeros-Weisenberger A, and Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48:884-893 https://doi.org/10.1097/chi.0b013e3181b26e9f
  10. Poncin Y, Sukhodolsky DG, McGuire J, and Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. Eur.Child Adolesc Psychiatry 2007; 16 Suppl 1:78-88 https://doi.org/10.1007/s00787-007-1010-8
  11. Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard H L, Allen A J, Milton DR, Feldman PD, Kelsey DK, Geller D A, Linder SL, Lewis DW, Winner PK, Kurlan RM, and Mintz M. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten.Disord. 2008:11:470-481 https://doi.org/10.1055/s-2006-945705
  12. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, and Spencer TJ. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65:1941-1949 https://doi.org/10.1212/01.wnl.0000188869.58300.a7
  13. Robertson M.M. Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: the relationship and treatment implications. A commentary. Eur.Child Adolesc.Psychiatry 2006; 15:1-11 https://doi.org/10.1007/s00787-006-0505-z
  14. McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, and Walker AM. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr.Drug Saf 2008;3:123-131 https://doi.org/10.2174/157488608784529233
  15. Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, Allen AJ, Ball S, and Dunn D. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol. 2007; 49:498-502 https://doi.org/10.1111/j.1469-8749.2007.00498.x
  16. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, and Heiligenstein J. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26:729-740 https://doi.org/10.2165/00002018-200326100-00006
  17. Vetter VL, Elia J, Erckson C, Berger S, Blum N, Uzark K, and Webb CL. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young. Circulation 2008; 117:2407-2423 https://doi.org/10.1161/circulationaha.107.189473
  18. Jackson LV, Thalange NK, and Cole TJ. Blood pressure centiles for Great Britain. Arch Dis.Child 2007; 92:298-303 https://doi.org/10.1136/adc.2005.081216
  19. Krzyzaniak A, Krzywinska-Wiewiorowska M, Stawinska-Witoszynska B, Kaczmarek M, Krzych L, Kowalska M, Szilagyi- Pagowska I, Palczewska I, Karch A, Josko J, Ostrowska-Nawarycz L, and Nawarycz T. Blood pressure references for Polish children and adolescents. Eur.J Pediatr 2009; 168:1335-1342 https://doi.org/10.1007/s00431-009-0931-2
  20. Marras AR, Bassareo PP, and Ruscazio M. The prevalence of paediatric hypertension, emphasising the need to use specific population references: the Sardinian Hypertensive Adolescents Research Programme Study. Cardiol.Young 2009; 19:233-238 https://doi.org/10.1017/s1047951109003722
  21. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445-1448 https://doi.org/10.1056/nejmp068049
  22. Neuspiel DR, and Kuller LH. Sudden and unexpected natural death in childhood and adolescence. JAMA 1985; 254:1321- 1325 https://doi.org/10.1001/jama.1985.03360100071016
  23. Wren C. Sudden death in children and adolescents. Heart 2002; 88:426-431 https://doi.org/10.1136/heart.88.4.426
  24. Berger S, Utech L, and Fran Hazinski M. Sudden death in children and adolescents. Pediatr Clin North Am 2004; 51: 1653-165x https://doi.org/10.1016/j.pcl.2004.07.004
  25. Corrado D, Basso C, and Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc.Res 2001; 50:399-408 https://doi.org/10.1016/s0008-6363(01)00254-1
  26. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, Trzepacz PT, and Allen A.J. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008; 47:209-218 https://doi.org/10.1097/chi.0b013e31815d88b2
  27. U.S Food and Drug Administration (2005) FDA Alert: Suicidal Thinking in Children.            
  28. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard H. W, Seibel JA, Vance ML, and Zimmerman D. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update. Endocr.Pract 2003; 9:64-76 https://doi.org/10.4158/ep.9.1.64
  29. Faraone SV, and Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007; 46:1138-1147 https://doi.org/10.1097/chi.0b013e31806ad1d7
  30. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells K C, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners C K, Caron M, and Volkow ND. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46:1015-1027 https://doi.org/10.1097/chi.0b013e3180686d7e
  31. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Geller D A, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ, and Allen AJ. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007; 17:689-700 https://doi.org/10.1089/cap.2006.0100
  32. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, and Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116:e74-e80 https://doi.org/10.1542/peds.2004-0624
  33. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga- Barke E, Steinhausen HC, and Zuddas A. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur.Child Adolesc.Psychiatry 2004; 13 Suppl 1:I7-30 https://doi.org/10.1007/s00787-004-1002-x
  34. Kollins SH, English J, Robinson R, Hallyburton M, and Chrisman AK. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology 2008; (Berl) https://doi.org/10.1007/s00213-008-1439-6
  35. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten.Disord 2008; 12:115-125 https://doi.org/10.1177/1087054707311654
  36. Wilens TE, Faraone SV, Biederman J, and Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179-185 https://doi.org/10.1542/peds.111.1.179
  37. Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliott GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn J H, Severe JB, and Wigal T. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007; 46:1028-1040 https://doi.org/10.1097/chi.0b013e3180686d96
  38. Volkow ND, and Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am.J Psychiatry 2003; 160:1909-1918 https://doi.org/10.1176/appi.ajp.160.11.1909
  39. Upadhyaya HP, Rose K, Wang W, O’Rourke K, Sullivan B, Deas D, and Brady KT. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc.Psychopharmacol 2005; 15:799-809 https://doi.org/10.1089/cap.2005.15.799
  40. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, and Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21-31 https://doi.org/10.1097/chi.0b013e31815a56f1
  41. Wilens TE, Gignac M, Swezey A, Monuteaux MC, and Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am.Acad.Child Adolesc.Psychiatry 2006; 45:408-414 https://doi.org/10.1097/01.chi.0000199027.68828.b3
  42. Jasinski DR, Faries DE, Moore RJ, Schuh LM, and Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95:140-146 https://doi.org/10.1016/j.drugalcdep.2008.01.008
  43. Mosholder AD, Gelperin K, Hammad TA, Phelan K, and Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123:611-616 https://doi.org/10.1542/peds.2008-0185
  44. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong I C K, Zuddas A, Steinhausen H-C, Taylor E. European Guidelines on managing adverse effects of medication for ADHD. Eur.Child Adolesc Psychiatry 2010; 20(1), 17-37. https://doi.org/10.1007/s00787-010-0140-6